We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Leica Microsystems Signs Distribution Agreement with French Company

By Biotechdaily staff writers
Posted on 10 Apr 2007
Leica Microsystems (Wetzlar, Germany) and Mauna Kea Technologies (MKT; Paris, France) signed an exclusive distribution agreement for the German high-tech optics company to market the innovative system developed by Mauna Kea Technologies. More...
The two companies are collaborating to improve research and to discover therapies against serious diseases worldwide

Leica Microsystems thus enlarges its product portfolio to include an endoscopic confocal microscope for in-vivo research applications. The agreement covers Europe, North America, and Japan. Cellvizio, as the system is called, will be adopted marketed as Leica FCM1000 (fiber-confocal microscope).

Leica FCM1000 with Cellvizio technology is a fiberoptic confocal fluorescence microscope for dynamic in vivo imaging. Its movable, minimally invasive probe allows it to be introduced non-destructively into the insides of living animals, producing video image sequences at a rate of 12 frames per second. There is a strongly increasing demand for in vivo microscopy, to complement classical in-vitro studies, so this new product is the ideal addition to our portfolio of state of the art confocal microscopes, explained Leica's executive vice president of sales and marketing, David Martyr.

This small animal imaging system is used in pre-clinical research in academic research institutions and biotechnologic and pharmaceutic companies. Primarily conducted on rodents, these experiments play a key role in neurologic research in deep brain and peripheral nerves imaging, especially in the research of degenerative diseases such as Alzheimer's and Parkinson's, and in cancer, cardiovascular and stem cell research, gene delivery, and tissue engineering.

Sacha Loiseau, president of Mauna Kea Technologies, explained, We are extremely proud of this major agreement between Mauna Kea Technologies and the prestigious company Leica Microsystems. It tangibly recognizes MKT's innovative R&D and leadership in non-invasive cellular and molecular imaging solutions. This achievement is the result of MKT's effort to gather the best team of scientists and engineers to develop new imaging technologies that are perfectly adapted to customer needs. The commercial agreement with Leica Microsystems will make it possible for thousands of researchers worldwide to benefit from the breakthroughs offered by Leica FCM1000 with Cellvizio technology.


Related Links:
Leica Microsystems
Mauna Kea Technologies

Gold Member
Troponin T QC
Troponin T Quality Control
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Vasculitis Diagnostic Test
AESKULISA Vasculitis-Screen
New
Plasmodium Test
Plasmodium DNA Real Time PCR Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: Switching to an experimental drug after liquid biopsy detection of breast cancer recurrence can improve outcomes (Photo courtesy of Shutterstock)

Treatment Switching Guided by Liquid Biopsy Blood Tests Improves Outcomes for Breast Cancer Patients

Standard treatment for patients with advanced estrogen receptor (ER)-positive, HER2-negative breast cancer, a subtype driven by estrogen receptors that fuel tumor growth, often involves aromatase inhibitors,... Read more

Pathology

view channel
Image: Microscopy image of invasive breast cancer cells degrading their underlying extracellular matrix (Photo courtesy of University of Turku)

Visualization Tool Illuminates Breast Cancer Cell Migration to Suggest New Treatment Avenues

Patients with breast cancer who progress from ductal carcinoma in situ (DCIS) to invasive ductal carcinoma (IDC) face a significantly worse prognosis, as metastatic disease remains incurable.... Read more

Technology

view channel
Image: The machine learning-based method delivers near-perfect survival estimates for PAC patients (Photo courtesy of Shutterstock)

AI Method Predicts Overall Survival Rate of Prostate Cancer Patients

Prostate adenocarcinoma (PAC) accounts for 99% of prostate cancer diagnoses and is the second most common cancer in men globally after skin cancer. With more than 3.3 million men in the United States diagnosed... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.